In oncology, crispr has revolutionized drug target discovery & validation
However, these screens are performed in cell-line models with unknown translability to the clinic.
However, these screens are performed in cell-line models with unknown translability to the clinic.
“We can't ethically conduct these experiments [screens] in people, but in a way, life has performed these experiments for us”
- Jennifer Doudna
Proprietary technology identifies the tissue & genetic background where drug target inhibition will cause cancer cell death. This analysis is performed before first patient is dosed with an inhibitor.
In “ Mother’s Nature” experiment, consistent with clinical data, MEK1 has a strong signal in BRAF tumors but not in KRAS tumors. Here is our workflow used to identify the right tissue & genetic background where your target inhibition will lead to cancer cell death.
A drug target candidate
Drug target gene status
Tumors for Machine Learning
Tumor types & genetics
Gordion identifies tumor type & genetic backgrounds, in which your drug target inhibition will deliver clinical success.
